Nathan Pennell, MD, PhD, Director of Lung Cancer Medical Oncology at the Cleveland Clinic Taussig Cancer Center in Cleveland Ohio discusses new options in acquired resistance for ALK positive non-small cell lung cancer (NSCLC).
Lung Cancer Video Library 2017 - New Options in Acquired Resistance for ALK Positive Non-small Cell Lung Cancer (NSCLC)
Lung Cancer Video Library - Is There An Optimal Chemo Regimen For Squamous Non-Small Cell Lung Cancer (NSCLC)
Dr. Jared Weiss, Vice President of GRACE and Associate Professor at UNC-Chapel Hill in Clinical Research, and the Thoracic Oncology Program at UNC Lineberger, discusses Is There An Optimal Chemo Regimen For Squamous Non-Small Cell Lung Cancer (NSCLC).
Lung Cancer Video Library - Is There A Role For PD-L1 Testing After First Line Treatment For Advanced Non-Small Cell Lung Cancer (NSCLC) In Those Previously Untested
Dr. Jared Weiss, Vice President of GRACE and Associate Professor at UNC-Chapel Hill in Clinical Research, and the Thoracic Oncology Program at UNC Lineberger, discusses if there is a role for PD-L1 testing after first line treatment.
Download the speaker presentations and handouts from the Targeted Therapies Patient Forum in Cleveland at the Taussig Cancer Center on September 16, 2017.
Dr. Luis Raez, MD FACP FCCP, Chief of Hematology/Oncology and Medical Director at Memorial Cancer Institute, and Clinical Associate Professor of Medicine at Florida International University joined GRACE to discuss second-line therapies for advanced NSCLC.
Dr. Jack West reviews the Lung Cancer Master Protocol for second line treatment of patients with advanced squamous NSCLC, an "umbrella protocol" in which all patients undergo molecular testing and have treatment assigned by the results.
Immune checkpoint inhibitors are now becoming approved and commercially available for patients with previously treated advanced NSCLC. Dr. Eddie Garon, medical oncologist at UCLA, summarizes key data and explains their current role in treatment.
In the span of a week, we’ve just had new FDA approvals of Keytruda (pembrolizumab) for previously treated advanced non-small cell lung cancer (NSCLC) patients with tumors that express PD-L1, followed by a broadened approval for Opdivo (nivolumab) for previously...
It's been a big week for immunotherapy for lung cancer. Right on the heels of a press release that the PD-1 inhibitor Opdivo (nivolumab)...
It was a big day for the lung cancer world. After seeing the tantalizing promise of immunotherapy for lung cancer over the past 3 years, but outside...
No Result Found